• MK-4827 (Niraparib): Redefining PARP Inhibition in Translati

  2026-07-29

  Explore the evolving landscape of PARP inhibition with MK-4827 (Niraparib), a selective and potent PARP-1/-2 inhibitor. This article bridges mechanistic insight and translational strategy, highlighting recent breakthroughs in overcoming chemoresistance, optimizing experimental protocols, and expanding the therapeutic reach of DNA damage repair inhibition in cancer research.

• Ac-YVAD-CMK: Precision Caspase-1 Inhibition in Inflammation

  2026-07-28

  Ac-YVAD-CMK (N-Ac-Tyr-Val-Ala-Asp-CMK) is a gold-standard tool for dissecting inflammatory responses through selective and irreversible Caspase-1 inhibition. This article translates new mechanistic insights from TMEM16F-Kupffer cell research into actionable protocols, troubleshooting, and advanced strategies for anti-inflammatory studies.

• DOT1L Inhibition Enhances Immune Drug Response in Myeloma

  2026-07-28

  This study demonstrates that DOT1L inhibition reprograms innate immunity in multiple myeloma, boosting the efficacy of immunomodulatory drugs like lenalidomide. The findings clarify epigenetic mechanisms underlying immune activation and highlight DOT1L as a promising therapeutic target in myeloma.

• Mubritinib (TAK 165): Redefining Mitochondrial Targeting in

  2026-07-27

  This thought-leadership article unpacks the evolving mechanistic understanding of Mubritinib (TAK 165) as a selective mitochondrial complex I inhibitor and its implications for translational oncology and virology. Integrating recent evidence, best practices, and strategic guidance, we provide a roadmap for researchers aiming to leverage Mubritinib in acute myeloid leukemia, primary effusion lymphoma, and virus-driven cancer models, while addressing translational challenges and future directions.

• Reversine: Aurora Kinase Inhibitor Workflows in Cancer Resea

  2026-07-27

  Reversine stands out as a robust Aurora kinase inhibitor for dissecting mitotic checkpoint regulation and driving apoptosis in cancer cell models. This guide details experimental workflows, highlights troubleshooting strategies, and translates new mechanistic insights from checkpoint biology into actionable protocol enhancements.

• IP3R/Ca2+/STAT3 Pathway Drives Apoptosis from Nanoplastics–C

  2026-07-26

  This study reveals how simultaneous exposure to polystyrene nanoplastics and cadmium induces apoptosis in intestinal cells by activating the IP3R/Ca2+/STAT3 pathway. The research employs both genetic and pharmacological tools to clarify calcium's central role in apoptosis triggered by environmental co-contaminants, providing mechanistic insight for toxicology and risk assessment.

• DGLA-Induced Ferroptosis via ACSL4 in AML: Mechanisms and Im

  2026-07-25

  This article analyzes new evidence that exogenous dihomo-γ-linolenic acid (DGLA) robustly induces ferroptosis in acute myeloid leukemia (AML) cells by reprogramming lipid metabolism via ACSL4. The findings highlight a promising metabolic vulnerability in AML and suggest potential strategies to overcome chemotherapy resistance.

• Branched Endosomal Disruptor Lipids Advance mRNA & RNP Deliv

  2026-07-24

  The referenced study introduces a new class of branched ionizable lipids (BEND lipids) that enhance the endosomal escape of mRNA and CRISPR-Cas9 ribonucleoprotein complexes. This innovation significantly improves gene editing efficiency in hepatocytes and T cells, addressing longstanding bottlenecks in mRNA-based therapeutic delivery.

• GSK343 (SKU A3449): Precision EZH2 Inhibition for Reproducib

  2026-07-24

  This article explores how GSK343 (SKU A3449), a highly selective and cell-permeable EZH2 inhibitor from APExBIO, addresses key laboratory challenges in epigenetic cancer research. Through scenario-driven Q&A, it demonstrates how GSK343 enables reliable histone H3K27 trimethylation inhibition, supports robust cell viability and proliferation assays, and offers validated, literature-backed workflow guidance for biomedical researchers.

• AO/PI Double Staining: Empowering Precision in Translational

  2026-07-23

  This thought-leadership article explores how mechanistic insights from dual Acridine Orange/Propidium Iodide staining redefine cell viability assays for translational researchers. Drawing connections to recent advances in rare cell capture and profiling, it offers strategic guidance for optimizing workflow reproducibility, clinical relevance, and assay fidelity—anchored by the AO/PI Double Staining Kit from APExBIO.

• Angiotensin 1/2 (2-7) Peptide: Applied Uses and Workflow Mas

  2026-07-23

  Angiotensin 1/2 (2-7) peptide stands out for high-purity, reliable solubility, and unique mechanistic value in vascular and viral pathogenesis research. This article delivers protocol enhancements, troubleshooting tips, and cross-domain insights to maximize reproducibility and expand experimental impact.

• Camostat Mesilate: Translational Leverage in Protease Inhibi

  2026-07-22

  This article delivers a strategic, mechanistic, and workflow-driven perspective on Camostat Mesilate as a next-generation tool for translational protease inhibition, with a focus on ENaC modulation, suppression of TGF-β signaling, and the competitive context of protein–protein interaction (PPI) inhibitor design. Integrating primary findings and advanced structure-guided approaches, it provides actionable guidance for researchers seeking to bridge basic mechanism and preclinical application.

• Pravastatin Sodium: Optimizing HMG-CoA Reductase Inhibition

  2026-07-22

  Pravastatin sodium offers precision for in vitro and in vivo cholesterol biosynthesis inhibition, supporting advanced cardiovascular and metabolic research. This guide delivers actionable protocol enhancements, troubleshooting insights, and evidence-aligned strategies for maximizing reproducibility and translational relevance.

• Resazurin Cell Viability Assay Kit: Precision for High-Throu

  2026-07-21

  The Resazurin Cell Viability Assay Kit streamlines live cell quantification with unmatched sensitivity, non-toxicity, and dual-mode readout—empowering high-throughput and delicate biological studies. Its robust, ready-to-use format and compatibility across cell types set it apart for advanced applications from skeletal disease to drug screening.

• WP1066, JAK2/STAT3 Inhibitor: Precision Tools for Tumor and

  2026-07-21

  WP1066, a potent cell-permeable JAK2/STAT3 inhibitor from APExBIO, enables rigorous dissection of cancer signaling and immune modulation, with robust applications in renal cell carcinoma, acute myeloid leukemia, and regenerative studies. This article delivers protocol-driven workflows, troubleshooting insights, and workflow enhancements tailored for advanced research in oncology and immunometabolism.

455 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page